✦ LIBER ✦

Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial

✍ Scribed by Vandenbark, Arthur A.; Chou, Yuan K.; Whitham, Ruth; Mass, Michele; Buenafe, Abigail; Liefeld, Diane; Kavanagh, Daniel; Cooper, Shelley; Hashim, George A.; Offner, Halina

Book ID: 109931687
Publisher: Nature Publishing Group
Year: 1996
Tongue: English
Weight: 778 KB
Volume: 2
Category: Article
ISSN: 1078-8956
DOI: 10.1038/nm1096-1109

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of multiple sclerosis with non

Treatment of multiple sclerosis with nonathymuline results of a double blind controlled pilot trial

✍ E. Roullet; P. Cesaro; J. Choay; N. Simon-Lavoine; J-D. Degos; R. Marteau 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Results of a phase I clinical trial of a

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations

✍ Darcy B Wilson; Anna B Golding; Richard A Smith; Tanya Dafashy; James Nelson; La 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 234 KB

Multiple sclerosis: failure of treatment

Multiple sclerosis: failure of treatment with verapamil in a pilot trial

✍ S. Komoly; G. Jakab; A. Fazekas 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 164 KB

HYPERBARIC OXYGEN AND MULTIPLE SCLEROSIS

HYPERBARIC OXYGEN AND MULTIPLE SCLEROSIS: SHORT-TERM RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL

✍ Barnes, MichaelP.; Cartlidge, NiallE.F.; Bates, David; French, JoyceM.; Shaw, Da 📂 Article 📅 1985 🏛 The Lancet 🌐 English ⚖ 443 KB

DOUBLE-BLIND CONTROLLED TRIAL OF IMMUNOS

DOUBLE-BLIND CONTROLLED TRIAL OF IMMUNOSUPPRESSION IN THE TREATMENT OF MULTIPLE SCLEROSIS: FINAL REPORT

✍ Mertin, J.; Kremer, M.; Knight, S.C.; Batchelor, J.R.; Halliday, A.M.; Rudge, P. 📂 Article 📅 1982 🏛 The Lancet 🌐 English ⚖ 562 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro